Eisai will present five-year lecanemab and real-world Alzheimer's data at CTAD 2026. Explore the key efficacy and safety questions.
Arrowhead Pharmaceuticals has reported up to 73% mean reduction in cerebrospinal-fluid tau at Day 105 after subcutaneous ARO-MAPT treatment in healthy volunteers. The findings support central nervous system target engagement and a potential quarterly dosing schedule, but cognitive benefit and effects on brain tau pathology remain unproven.
Jocasta Neuroscience and Diamond Therapeutics will evaluate three psychedelic-inspired 5-HT2A receptor compounds for cognitive impairment and neurodegeneration. The agreement gives Jocasta an option to license successful candidates, but the molecules have not yet demonstrated clinical efficacy or an absence of hallucinogenic effects in humans.
Blood tests measuring phosphorylated tau and amyloid-related biomarkers can identify Alzheimer’s-associated brain pathology with high accuracy, but they are not interchangeable with population screening or a complete dementia diagnosis.
Preliminary Phase 1 data showed brain exposure, a half-life above 30 hours and dose-dependent IL-1β inhibition for AC Immune’s oral NLRP3 inhibitor ACI-19764.
Cortechs.ai’s NeuroQuant PET can automatically quantify amyloid PET uptake, generate SUVR and Centiloid measurements and send structured results into imaging workflows.
C2N Diagnostics’ FDA-cleared PrecivityAD2 combines amyloid and tau measurements in a mass-spectrometry test intended to aid assessment of symptomatic adults aged 40 and older.
Renew Biotechnologies has published peer-reviewed proof-of-concept research showing that native cell-free DNA methylation sequencing can recover neuron-associated blood signals that differ across Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. The results strengthen the scientific rationale behind its NeuroLens platform, but the decisive next step is independent, prospective validation in larger and more diverse patient
ALZpath expands its Alamar Biosciences deal into clinical diagnostics, opening a new path for pTau217 blood tests in Alzheimer’s disease.
Fapon unveils AI-engineered PCR enzymes and Alzheimer’s biomarker reagents at ADLM 2026, targeting faster North American IVD development.